GenAssist Therapeutics
Company Type: Therapeutic development
Main focus: Developing optimised bas-editing therapies for Duchenne muscular dystrophy
Company stage: Pre-clinical
Diseases: Duchenne muscular dystrophy
Genome-editing tool: TAM base editing
Funding stage: Series A
Location: Suzhou, Jiangsu, China
Website: genassisttx.com
Pipeline: genassisttx.com/pipeline/
Partners:
GenAssist Therapeutics is a biotech company based in China focusing on the development of advanced and optimised base-editing therapeutics to treat Duchenne muscular dystrophy (DMD) and eventually other diseases. The company utilises Targeted AID-mediated mutagenesis (TAM) base-editing technology to modify target DNA. The company is currently investigating several different editing outcomes including exon skipping, activating alternative splice sites, and editing splicing regulatory elements.